ANDA 206309, held by Rising. Temozolomide.
As of Nov 16, 2026, ANDA 206309 (Temozolomide), held by Rising, was first approved by FDA on Apr 27, 2016, with 3 approved supplements and 0 published complete response letters.
Temozolomide is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. Anaplastic astrocytoma. Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. Treatment of adults with refractory anaplastic astrocytoma. 1.1 Newly Diagnosed Glioblastoma Temozolomide capsules are indicated for the treatment of adults with newly diagnosed glioblastoma, concomitantly with radiotherapy and then as maintenance treatment. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 2016 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Rx |
| Temozolomide20MG · capsule;oral | Temozolomide | Rx |
| Temozolomide100MG · capsule;oral | Temozolomide | Rx |
| Temozolomide140MG · capsule;oral | Temozolomide | Rx |
| Temozolomide180MG · capsule;oral | Temozolomide | Rx |
| Temozolomide250MG · capsule;oral | Temozolomide | Rx |
| Jul 15, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 27, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 27, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 27, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters